Adimmune Corp (4142) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.073x

Based on the latest financial reports, Adimmune Corp (4142) has a cash flow conversion efficiency ratio of -0.073x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-355.08 Million ≈ $-11.19 Million USD) by net assets (NT$4.85 Billion ≈ $152.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Adimmune Corp (4142) balance sheet quality index to measure how much of total assets are equity-financed.

Adimmune Corp - Cash Flow Conversion Efficiency Trend (2007–2024)

This chart illustrates how Adimmune Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Adimmune Corp's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Adimmune Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Adimmune Corp ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
AURORA EIENDOM NK 75 F:IL7	N/A
Shin Yang Shipping Corporation Bhd KLSE:5173	0.046x
Hexindo Adiperkasa Tbk JK:HEXA	0.038x
Rani Zim Shopping Centers TA:RANI	0.015x
Journey Energy Inc TO:JOY	0.041x
Udaipur Cement Works Limited NSE:UDAICEMENT	0.038x
Mecaro Co. Ltd KQ:241770	0.011x
Shanghai Sanmao Enterprise Group Co Ltd A SHG:600689	-0.024x

Annual Cash Flow Conversion Efficiency for Adimmune Corp (2007–2024)

The table below shows the annual cash flow conversion efficiency of Adimmune Corp from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see Adimmune Corp (4142) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$5.56 Billion ≈ $175.22 Million	NT$668.48 Million ≈ $21.06 Million	0.120x	+177.82%
2023-12-31	NT$5.78 Billion ≈ $182.03 Million	NT$-892.35 Million ≈ $-28.11 Million	-0.154x	-246.22%
2022-12-31	NT$6.54 Billion ≈ $206.20 Million	NT$-291.96 Million ≈ $-9.20 Million	-0.045x	+40.28%
2021-12-31	NT$6.43 Billion ≈ $202.66 Million	NT$-480.52 Million ≈ $-15.14 Million	-0.075x	-121.33%
2020-12-31	NT$6.63 Billion ≈ $208.84 Million	NT$2.32 Billion ≈ $73.15 Million	0.350x	+630.21%
2019-12-31	NT$3.83 Billion ≈ $120.53 Million	NT$-252.72 Million ≈ $-7.96 Million	-0.066x	+79.62%
2018-12-31	NT$1.86 Billion ≈ $58.48 Million	NT$-601.74 Million ≈ $-18.96 Million	-0.324x	-11178.96%
2017-12-31	NT$2.35 Billion ≈ $74.02 Million	NT$6.87 Million ≈ $216.57K	0.003x	+101.17%
2016-12-31	NT$3.09 Billion ≈ $97.51 Million	NT$-773.53 Million ≈ $-24.37 Million	-0.250x	-146.38%
2015-12-31	NT$3.68 Billion ≈ $116.09 Million	NT$-373.82 Million ≈ $-11.78 Million	-0.101x	-8.59%
2014-12-31	NT$4.47 Billion ≈ $140.75 Million	NT$-417.35 Million ≈ $-13.15 Million	-0.093x	+46.82%
2013-12-31	NT$3.24 Billion ≈ $101.99 Million	NT$-568.64 Million ≈ $-17.92 Million	-0.176x	-60.56%
2012-12-31	NT$3.74 Billion ≈ $117.92 Million	NT$-409.48 Million ≈ $-12.90 Million	-0.109x	-34.00%
2011-12-31	NT$3.60 Billion ≈ $113.37 Million	NT$-293.77 Million ≈ $-9.26 Million	-0.082x	-164.23%
2010-12-31	NT$4.06 Billion ≈ $127.99 Million	NT$516.39 Million ≈ $16.27 Million	0.127x	-20.26%
2009-12-31	NT$3.77 Billion ≈ $118.67 Million	NT$600.42 Million ≈ $18.92 Million	0.159x	+472.28%
2008-12-31	NT$3.17 Billion ≈ $99.84 Million	NT$-135.69 Million ≈ $-4.28 Million	-0.043x	-363.61%
2007-12-31	NT$1.92 Billion ≈ $60.63 Million	NT$31.26 Million ≈ $984.86K	0.016x	--

About Adimmune Corp

TW:4142 Taiwan Biotechnology

Market Cap

$219.78 Million

NT$6.98 Billion TWD

Market Cap Rank

#16142 Global

#742 in Taiwan

Share Price

NT$16.55

Change (1 day)

+0.00%

52-Week Range

NT$16.55 - NT$21.55

All Time High

NT$77.19